Learn About Primary Hyperoxaluria Type 1
- Primary hyperoxaluria type 1
- Alanine-glyoxylate aminotransferase deficiency
- Glycolic aciduria
- HP1
- Hepatic AGT deficiency
- Oxalosis 1
- Peroxisomal alanine glyoxylate aminotransferase deficiency
- Serine pyruvate aminotransferase deficiency
Pierre Cochat practices in Bron, France. Mr. Cochat is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. His top areas of expertise are Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.
Yaacov Frishberg practices in Jerusalem, Israel. Mr. Frishberg is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. His top areas of expertise are Primary Hyperoxaluria Type 1, Primary Hyperoxaluria, Nephrocalcinosis, Calcinosis, and Kidney Transplant.
Mayo Clinic
John Lieske is a Nephrologist in Rochester, Minnesota. Dr. Lieske is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 1. His top areas of expertise are Kidney Stones, Nephrocalcinosis, Primary Hyperoxaluria, Kidney Transplant, and Lithotripsy. Dr. Lieske is currently accepting new patients.
Summary: The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Summary: The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pedia...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center